SYNERGISTIC CYTOTOXIC EFFECTS OF THE COMBINATION OF ERLOTINIB AND EXO2 ON HEAD AND NECK CANCER

Date

2019-05

Authors

Thakkar, Parth

Journal Title

Journal ISSN

Volume Title

Publisher

Augusta University

Abstract

More than 90% of head and neck cancer is head and neck squamous cell carcinoma1 (HNSCC). Currently, the treatment involves modern surgery, conventional chemotherapy, and radiation. However, targeting, the epidermal growth factor receptor (EGFR) has been shown to prove advantageous for patient survival. EGFR activation leads to cell cycle progression. Blocking the EGFR by an antibody results in the inhibition of the receptor, therefore inhibition of cell proliferation. This makes EGFR a prime target for anticancer therapy, specifically with tyrosine kinase inhibitors being looked at as a possible form of inhibition. The goal of this project was to hopefully use small molecule inhibitor EXO2 and an EGFR specific tyrosine kinase inhibitor, erlotinib, in a synergistic manner to fight against HNSCC. We hypothesize that the usage of both drugs together in a synergistic manner will prove to be a more effective treatment against HNSCC then using either drug alone. This study was done using cell cultures, MTT assay’s and western blot techniques, with cell cultures being done using the H6 cell line. The results from this study were found show a synergistic effect between EXO2 and erlotinib, supporting the hypothesis, but further studies into each drug individually as well s the interaction between both drugs must be done in future experiments.

Description

This file is restricted to Augusta University. Please log in using your JagNet ID and password to access.

Keywords

Citation

DOI